EP4754530A1 - Epha1 sérique utilisé en tant que biomarqueur pour l'endométriose - Google Patents

Epha1 sérique utilisé en tant que biomarqueur pour l'endométriose

Info

Publication number
EP4754530A1
EP4754530A1 EP24748936.2A EP24748936A EP4754530A1 EP 4754530 A1 EP4754530 A1 EP 4754530A1 EP 24748936 A EP24748936 A EP 24748936A EP 4754530 A1 EP4754530 A1 EP 4754530A1
Authority
EP
European Patent Office
Prior art keywords
endometriosis
epha1
subject
uterine
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24748936.2A
Other languages
German (de)
English (en)
Inventor
Deirdre Mary ALLEGRANZA
Aljoscha Michael FLOHR
Martin Hund
Martin KLAMMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Original Assignee
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Roche Diagnostics GmbH filed Critical F Hoffmann La Roche AG
Publication of EP4754530A1 publication Critical patent/EP4754530A1/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés pour diagnostiquer si un sujet présente une endométriose, une pathologie utérine/pelvienne et/ou une endométriose et/ou une douleur neuropathique associée à une pathologie utérine/pelvienne, des procédés de détermination de l'effet thérapeutique d'un régime de traitement pour l'endométriose, une pathologie utérine/pelvienne et/ou une endométriose et/ou une douleur neuropathique associée à une pathologie utérine/pelvienne, et des procédés de surveillance de l'endométriose, de la pathologie utérine/pelvienne et/ou de l'endométriose et/ou de la progression de la douleur neuropathique associée à une pathologie utérine/pelvienne chez un sujet, par détermination de la quantité ou de la concentration d'EphA1 dans un échantillon du sujet, et comparaison du niveau déterminé à une valeur de référence.
EP24748936.2A 2023-07-28 2024-07-26 Epha1 sérique utilisé en tant que biomarqueur pour l'endométriose Pending EP4754530A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23188461 2023-07-28
PCT/EP2024/071268 WO2025026908A1 (fr) 2023-07-28 2024-07-26 Epha1 sérique utilisé en tant que biomarqueur pour l'endométriose

Publications (1)

Publication Number Publication Date
EP4754530A1 true EP4754530A1 (fr) 2026-06-10

Family

ID=87519981

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24748936.2A Pending EP4754530A1 (fr) 2023-07-28 2024-07-26 Epha1 sérique utilisé en tant que biomarqueur pour l'endométriose

Country Status (4)

Country Link
EP (1) EP4754530A1 (fr)
JP (1) JP2026526931A (fr)
CN (1) CN121752901A (fr)
WO (1) WO2025026908A1 (fr)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316757A (en) 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
US5342606A (en) 1984-10-18 1994-08-30 Board Of Regents, The University Of Texas System Polyazamacrocyclic compounds for complexation of metal ions
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
WO1987006706A1 (fr) 1986-04-30 1987-11-05 Igen, Inc. Analyses electrochimiluminescentes
US5591581A (en) 1986-04-30 1997-01-07 Igen, Inc. Electrochemiluminescent rhenium moieties and methods for their use
JPH076913B2 (ja) 1988-11-03 1995-01-30 イゲン，インコーポレーテッド アミン誘導還元剤を利用する電気化学発光反応
DE68928994T2 (de) 1988-11-03 1999-12-16 Igen International, Inc. Elektrochemilumineszente testverfahren
IL100867A (en) 1991-02-06 1995-12-08 Igen Inc Method and apparatus for improved luminescence assays
US5739294A (en) 1991-12-10 1998-04-14 The Dow Chemical Company Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents
US5480990A (en) 1991-12-10 1996-01-02 The Dow Chemical Company Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
ZA929351B (en) 1991-12-11 1993-06-04 Igen Inc Electrochemiluminescent label for DNA assays.
US5385893A (en) 1993-05-06 1995-01-31 The Dow Chemical Company Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
US5462725A (en) 1993-05-06 1995-10-31 The Dow Chemical Company 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
US5834461A (en) 1993-07-29 1998-11-10 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JPH09505464A (ja) 1993-09-22 1997-06-03 イゲン，インコーポレーテッド 自立性配列複製電気化学発光核酸測定法
CA2198489A1 (fr) 1994-08-26 1996-03-07 Igen International, Inc. Biodetecteur et methode de detection chimioluminescente a electrogeneration pour l'acide nudeique adsorbe sur une surface solide
US5786141A (en) 1994-08-26 1998-07-28 Bard; Allen J. Electrogenerated chemiluminescence labels for analysis and/or referencing
US5643713A (en) 1995-06-07 1997-07-01 Liang; Pam Electrochemiluminescent monitoring of compounds
US6852502B1 (en) 1995-06-06 2005-02-08 Bioveris Corporation Electrochemiluminescent enzyme biosensors
WO1996033411A1 (fr) 1995-04-18 1996-10-24 Igen, Inc. L'electrochimioluminescence de chelates de metaux de terres rares
US5679519A (en) 1995-05-09 1997-10-21 Oprandy; John J. Multi-label complex for enhanced sensitivity in electrochemiluminescence assay
ES2285713T3 (es) 1995-06-07 2007-11-16 Bioveris Corporation Enzimoinmunoanalisis electroquimioluminiscente.
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US8367332B2 (en) 2008-10-31 2013-02-05 Case Western Reserve University Detection and quantification of abasic site formation in vivo
MX342921B (es) 2011-02-09 2016-10-19 Hoffmann La Roche Nuevos complejos a base de iridio para electroquimioluminiscencia (ecl).
TW201401798A (zh) 2012-06-28 2014-01-01 Chunghwa Telecom Co Ltd ＦＴＴｘ光終端設備之用戶端動態多路由饋電系統
JP6072072B2 (ja) 2012-12-12 2017-02-01 株式会社東芝 クラウドシステム管理装置、クラウドシステム、再配置方法、及びプログラム
JP5922639B2 (ja) 2013-12-07 2016-05-24 レノボ・シンガポール・プライベート・リミテッド 折り畳み式の電子機器、表示システム、および表示方法
US9716942B2 (en) 2015-12-22 2017-07-25 Bose Corporation Mitigating effects of cavity resonance in speakers
JP7535270B2 (ja) * 2019-04-26 2024-08-16 中外製薬株式会社 子宮内膜症の診断方法、病態モニタリング方法及びキット
WO2022207628A1 (fr) * 2021-03-30 2022-10-06 F. Hoffmann-La Roche Ag Scf comme biomarqueur sanguin pour le diagnostic non invasif de l'endométriose
EP4341700A1 (fr) * 2021-05-17 2024-03-27 F. Hoffmann-La Roche AG Sfrp4 en tant que biomarqueur sanguin pour le diagnostic non invasif de l'adénomyose

Also Published As

Publication number Publication date
WO2025026908A1 (fr) 2025-02-06
CN121752901A (zh) 2026-03-27
JP2026526931A (ja) 2026-08-10

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260226

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR